{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T01:16:08Z","timestamp":1728177368061},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,27]]},"DOI":"10.7759\/cureus.46090","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T02:17:11Z","timestamp":1695867431000},"source":"Crossref","is-referenced-by-count":2,"title":["Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan"],"prefix":"10.7759","author":[{"given":"Noriyuki","family":"Naya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012509.pub2","article-title":"Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews","volume":"10","author":"Els C","year":"2017","unstructured":"Els C, Jackson TD, Kunyk D, et al.. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017, 10:CD012509. 10.1002\/14651858.CD012509.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640618818305","article-title":"Pathophysiology and management of opioid-induced constipation: European expert consensus statement","volume":"7","author":"Farmer AD","year":"2019","unstructured":"Farmer AD, Drewes AM, Chiarioni G, De Giorgio R, O'Brien T, Morlion B, Tack J. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol J. 2019, 7:7-20. 10.1177\/2050640618818305","journal-title":"United European Gastroenterol J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2341","article-title":"Incidence of opioid-induced constipation in Japanese patients with cancer pain: a prospective observational cohort study","volume":"8","author":"Tokoro A","year":"2019","unstructured":"Tokoro A, Imai H, Fumita S, et al.. Incidence of opioid-induced constipation in Japanese patients with cancer pain: a prospective observational cohort study. Cancer Med. 2019, 8:4883-91. 10.1002\/cam4.2341","journal-title":"Cancer Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/2050640618786145","article-title":"The patient burden of opioid-induced constipation: new insights from a large, multinational survey in five European countries","volume":"6","author":"Andresen V","year":"2018","unstructured":"Andresen V, Banerji V, Hall G, Lass A, Emmanuel AV. The patient burden of opioid-induced constipation: new insights from a large, multinational survey in five European countries. United European Gastroenterol J. 2018, 6:1254-66. 10.1177\/2050640618786145","journal-title":"United European Gastroenterol J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01766-y","article-title":"Management of opioid-induced constipation and bowel dysfunction: expert opinion of an Italian multidisciplinary panel","volume":"38","author":"De Giorgio R","year":"2021","unstructured":"De Giorgio R, Zucco FM, Chiarioni G, et al.. Management of opioid-induced constipation and bowel dysfunction: expert opinion of an Italian multidisciplinary panel. Adv Ther. 2021, 38:3589-621. 10.1007\/s12325-021-01766-y","journal-title":"Adv Ther"},{"key":"ref6","article-title":"Guidelines for Drug Therapy for Cancer Pain (2020 Edition)","author":"Japanese Society for Palliative Medicine Guideline Management Committee","year":"2020","unstructured":"Japanese Society for Palliative Medicine Guideline Management Committee. Guidelines for Drug Therapy for Cancer Pain (2020 Edition). Kanehara Publishing Co., Ltd., Tokyo, Japan; 2020. https:\/\/www.jspm.ne.jp\/publication\/guidelines\/individual.html?entry_id=85."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation","volume":"156","author":"Crockett SD","year":"2019","unstructured":"Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019, 156:218-26. 10.1053\/j.gastro.2018.07.016","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0686-6","article-title":"Opioid-induced constipation in oncological patients: new strategies of management","volume":"20","author":"Mes\u00eda R","year":"2019","unstructured":"Mes\u00eda R, Virizuela Echaburu JA, G\u00f3mez J, Sauri T, Serrano G, Pujol E. Opioid-induced constipation in oncological patients: new strategies of management. Curr Treat Options Oncol. 2019, 20:91. 10.1007\/s11864-019-0686-6","journal-title":"Curr Treat Options Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S221278","article-title":"The use of peripheral \u03bc-opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety","volume":"14","author":"Pergolizzi JV Jr","year":"2020","unstructured":"Pergolizzi JV Jr, Christo PJ, LeQuang JA, Magnusson P. The use of peripheral \u03bc-opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety. Drug Des Devel Ther. 2020, 14:1009-25. 10.2147\/DDDT.S221278","journal-title":"Drug Des Devel Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16201","article-title":"Efficacy and safety of peripherally acting \u03bc-opioid receptor antagonist (PAMORAs) for the management of patients with opioid-induced constipation: a systematic review","volume":"13","author":"Rekatsina M","year":"2021","unstructured":"Rekatsina M, Paladini A, Drewes AM, et al.. Efficacy and safety of peripherally acting \u03bc-opioid receptor antagonist (PAMORAs) for the management of patients with opioid-induced constipation: a systematic review. Cureus. 2021, 13:e16201. 10.7759\/cureus.16201","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13563","article-title":"Pharmacologic effects of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation","volume":"31","author":"Kanemasa T","year":"2019","unstructured":"Kanemasa T, Koike K, Arai T, et al.. Pharmacologic effects of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation. Neurogastroenterol Motil. 2019, 31:e13563. 10.1111\/nmo.13563","journal-title":"Neurogastroenterol Motil"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.11.007","article-title":"Discovery of naldemedine: a potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects","volume":"29","author":"Inagaki M","year":"2019","unstructured":"Inagaki M, Kume M, Tamura Y, et al.. Discovery of naldemedine: a potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects. Bioorg Med Chem Lett. 2019, 29:73-7. 10.1016\/j.bmcl.2018.11.007","journal-title":"Bioorg Med Chem Lett"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.01.021","article-title":"Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis","volume":"16","author":"Nee J","year":"2018","unstructured":"Nee J, Zakari M, Sugarman MA, et al.. Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018, 16:1569-84.e2. 10.1016\/j.cgh.2018.01.021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-00976-y","article-title":"Constipation in cancer patients - an update of clinical evidence","volume":"23","author":"Dzier\u017canowski T","year":"2022","unstructured":"Dzier\u017canowski T, Mercadante S. Constipation in cancer patients - an update of clinical evidence. Curr Treat Options Oncol. 2022, 23:936-50. 10.1007\/s11864-022-00976-y","journal-title":"Curr Treat Options Oncol"},{"key":"ref15","unstructured":"European Medicines Agency. Rizmoic. (2019). Accessed. December 9, 2022: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rizmoic."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0750-0","article-title":"Naldemedine: first global approval","volume":"77","author":"Markham A","year":"2017","unstructured":"Markham A. Naldemedine: first global approval. Drugs. 2017, 77:923-7. 10.1007\/s40265-017-0750-0","journal-title":"Drugs"},{"key":"ref17","unstructured":"Taiwan Food and Drug Administration. Assessment report. naldemedine tosylate. (2021). https:\/\/www.fda.gov.tw\/tc\/includes\/GetFile.ashx?id=f637738690978327922&type=2&cid=39298."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(17)30105-x","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale M","year":"2017","unstructured":"Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017, 2:555-64. 10.1016\/s2468-1253(17)30105-x","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer","volume":"35","author":"Katakami N","year":"2017","unstructured":"Katakami N, Harada T, Murata T, et al.. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017, 35:3859-66. 10.1200\/JCO.2017.73.0853","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S175900","article-title":"Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies","volume":"12","author":"Saito Y","year":"2019","unstructured":"Saito Y, Yokota T, Arai M, Tada Y, Sumitani M. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies. J Pain Res. 2019, 12:127-38. 10.2147\/JPR.S175900","journal-title":"J Pain Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001174","article-title":"Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study","volume":"159","author":"Webster LR","year":"2018","unstructured":"Webster LR, Nalamachu S, Morlion B, Reddy J, Baba Y, Yamada T, Arjona Ferreira JC. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain. 2018, 159:987-94. 10.1097\/j.pain.0000000000001174","journal-title":"Pain"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06807-y","article-title":"Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan","volume":"30","author":"Takata K","year":"2022","unstructured":"Takata K, Nakazawa M, Honda K, Hashimoto S. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan. Support Care Cancer. 2022, 30:3943-54. 10.1007\/s00520-022-06807-y","journal-title":"Support Care Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000527","article-title":"Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies","volume":"4","author":"Osaka I","year":"2019","unstructured":"Osaka I, Ishiki H, Yokota T, Tada Y, Sato H, Okamoto M, Satomi E. Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies. ESMO Open. 2019, 4:e000527. 10.1136\/esmoopen-2019-000527","journal-title":"ESMO Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy118","article-title":"Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer","volume":"29","author":"Katakami N","year":"2018","unstructured":"Katakami N, Harada T, Murata T, et al.. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol. 2018, 29:1461-7. 10.1093\/annonc\/mdy118","journal-title":"Ann Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14011383","article-title":"Role of the blood-brain barrier in the formation of brain metastases","volume":"14","author":"Wilhelm I","year":"2013","unstructured":"Wilhelm I, Moln\u00e1r J, Fazakas C, Hask\u00f3 J, Krizbai IA. Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci. 2013, 14:1383-411. 10.3390\/ijms14011383","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.14201","article-title":"Toward the development of a vibrant, super-aged society: the future of medicine and society in Japan","volume":"21","author":"Iijima K","year":"2021","unstructured":"Iijima K, Arai H, Akishita M, et al.. Toward the development of a vibrant, super-aged society: the future of medicine and society in Japan. Geriatr Gerontol Int. 2021, 21:601-13. 10.1111\/ggi.14201","journal-title":"Geriatr Gerontol Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/1049909111410965","article-title":"Symptom prevalence in advanced cancer: age, gender, and performance status interactions","volume":"29","author":"Kirkova J","year":"2012","unstructured":"Kirkova J, Rybicki L, Walsh D, Aktas A. Symptom prevalence in advanced cancer: age, gender, and performance status interactions. Am J Hosp Palliat Care. 2012, 29:139-45. 10.1177\/1049909111410965","journal-title":"Am J Hosp Palliat Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2022.02.007","article-title":"Chemotherapy induced gastrointestinal toxicities","volume":"155","author":"Akbarali HI","year":"2022","unstructured":"Akbarali HI, Muchhala KH, Jessup DK, Cheatham S. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res. 2022, 155:131-66. 10.1016\/bs.acr.2022.02.007","journal-title":"Adv Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b21-00209","article-title":"Analysis of predictive factors for diarrhea after the administration of naldemedine","volume":"44","author":"Hashizume J","year":"2021","unstructured":"Hashizume J, Shiojiri K, Ryu E, et al.. Analysis of predictive factors for diarrhea after the administration of naldemedine. Biol Pharm Bull. 2021, 44:1081-7. 10.1248\/bpb.b21-00209","journal-title":"Biol Pharm Bull"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4103\/IJPC.IJPC_171_19","article-title":"Fentanyl, morphine, and opioid-induced constipation in patients with cancer-related pain","volume":"26","author":"Ghoshal A","year":"2020","unstructured":"Ghoshal A. Fentanyl, morphine, and opioid-induced constipation in patients with cancer-related pain. Indian J Palliat Care. 2020, 26:535-6. 10.4103\/IJPC.IJPC_171_19","journal-title":"Indian J Palliat Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/169192-real-world-evidence-for-the-safety-and-effectiveness-of-naldemedine-in-the-management-of-opioid-induced-constipation-in-patients-with-cancer-pain-post-hoc-subgroup-analysis-of-post-marketing-surveillance-in-japan","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:07Z","timestamp":1707509227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/169192-real-world-evidence-for-the-safety-and-effectiveness-of-naldemedine-in-the-management-of-opioid-induced-constipation-in-patients-with-cancer-pain-post-hoc-subgroup-analysis-of-post-marketing-surveillance-in-japan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.46090","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}